European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared from a/vietnam/1194/2004 nibrg-14 (h5n1) (see section 5.1).prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals 3.75 µg should be used in accordance with official guidance.

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - salbutamol sulphate eqv salbutamol - injection - 5 mg/5 ml - salbutamol sulphate eqv salbutamol 5 mg/5 ml

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - epoprostenol - injection, powder, for solution - 0.5 mg/vial - epoprostenol 0.5 mg/vial

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline manufacturing s.p.a. - ceftazidime (ceftazidime pentahydrate) - powder for solution for injection/infusion - 500mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline manufacturing s.p.a. - ceftazidime (ceftazidime pentahydrate) - powder for solution for injection/infusion - 1000mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline manufacturing spa - ceftazidime (ceftazidime pentahydrate) - powder for solution for injection/infusion - 500mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline manufacturing s.p.a. - ceftazidime (ceftazidime pentahydrate) - powder for solution for injection/infusion - 1000mg

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 120.5ug equivalent to 100 µg dose (10% excess may be added to compensate for manufacturing loss);   - aerosol inhaler, metered dose - 100 mcg/dose - active: salbutamol sulfate 120.5ug equivalent to 100 µg dose (10% excess may be added to compensate for manufacturing loss)   excipient: norflurane - salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting (four hours) bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. for patients with asthma salbutamol may be used to relieve symptoms when they occur and to prevent them prior to a known trigger. bronchodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failure to respond promptly or fully to such rescue medication signals a need for urgent medical advice and treatment.

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - live attenuated measles virus (schwarz strain); live attenuated mumps virus (rit4385 strain); live attenuated rubella virus (wistar ra 27/3 strain); live attenuated varicella virus (oka strain) - injection, powder, lyophilized, for solution - ≥ 10 3.0 ccid50 /dose - live attenuated measles virus (schwarz strain) ≥ 10³ ccid50/dose; live attenuated mumps virus (rit4385 strain) ≥ 10⁴·⁴ ccid50/dose; live attenuated rubella virus (wistar ra 27/3 strain) ≥ 10³ ccid50/dose; live attenuated varicella virus (oka strain) ≥ 10³·³ pfu/dose

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human - vaccines - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.